» Articles » PMID: 32596339

D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2020 Jun 30
PMID 32596339
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the value of coagulation indicators D-dimer (DD), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (Fg) in predicting the severity and prognosis of COVID-19.

Methods: A total of 115 patients with confirmed COVID-19, who were admitted to Tianyou Hospital of Wuhan University of Science and Technology between January 18, 2020, and March 5, 2020, were included. The dynamic changes of DD, PT, APTT, and Fg were tested, and the correlation with CT imaging, clinical classifications, and prognosis was studied.

Results: Coagulation disorder occurred at the early stage of COVID-19 infection, with 50 (43.5%) patients having DD increased and 74 (64.3%) patients having Fg increased. The levels of DD and Fg were correlated with clinical classification. Among 23 patients who deceased, 18 had DD increased at the first lab test, 22 had DD increased at the second and third lab tests, and 18 had prolonged PT at the third test. The results from ROC analyses for mortality risk showed that the AUCs of DD were 0.742, 0.818, and 0.851 in three times of test, respectively; PT was 0.643, 0.824, and 0.937. In addition, with the progression of the disease, the change of CT imaging was closely related to the increase of the DD value ( < 0.01).

Conclusions: Coagulation dysfunction is more likely to occur in severe and critically ill patients. DD and PT could be used as the significant indicators in predicting the mortality of COVID-19.

Citing Articles

Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study.

Nwose E, Bwititi P Med Sci (Basel). 2025; 13(1).

PMID: 39982245 PMC: 11843925. DOI: 10.3390/medsci13010020.


Unveiling coagulation dysfunction in patients with COVID-19: a retrospective analysis.

Jerah A, Farasani A, Abu-Tawil H, Kuriri H, Taha M, Abdelwahab S J Med Life. 2024; 17(9):886-891.

PMID: 39628975 PMC: 11611055. DOI: 10.25122/jml-2024-0166.


Fragmentomics of plasma mitochondrial and nuclear DNA inform prognosis in COVID-19 patients with critical symptoms.

Zhang H, Li L, Luo Y, Zheng F, Zhang Y, Xie R BMC Med Genomics. 2024; 17(1):243.

PMID: 39363185 PMC: 11451003. DOI: 10.1186/s12920-024-02022-2.


Alterations in hematologic, coagulation, and inflammatory markers based on fever status in hospitalized COVID-19 patients: A retrospective study.

Chatterjee B, Modi N, Desai K, Murugan Y, Trivedi A J Family Med Prim Care. 2024; 13(8):3220-3224.

PMID: 39228600 PMC: 11368334. DOI: 10.4103/jfmpc.jfmpc_226_24.


Soluble platelet selectin and platelets in COVID-19: a multifaceted connection.

Obeagu E, Obeagu G, Aja P, Okoroiwu G, Ubosi N, Pius T Ann Med Surg (Lond). 2024; 86(8):4634-4642.

PMID: 39118706 PMC: 11305715. DOI: 10.1097/MS9.0000000000002302.


References
1.
Zhou T, Liu Q, Yang Z, Liao J, Yang K, Bai W . Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV. J Evid Based Med. 2020; 13(1):3-7. PMC: 7167008. DOI: 10.1111/jebm.12376. View

2.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

3.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

4.
Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

5.
Cohen J . The immunopathogenesis of sepsis. Nature. 2002; 420(6917):885-91. DOI: 10.1038/nature01326. View